Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma

Xu, Ying; Zheng, Wenhua; Li, Fufeng

doi:10.1016/j.tranon.2020.100957

Cited by 21 publications

(11 citation statements)

References 39 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IPS was proved to be a predictor of response to checkpoint blockers in patients with melanoma. IPS may serve as a useful tool for evaluating the efficacy of ICIs ( 55 ) and this view was verified in recent study. Furthermore, the close associations of sensitivity to tumor immunotherapy with immune checkpoint genes and tumor immune infiltration ( 56 , 57 ).…”

Section: Discussionmentioning

confidence: 56%

Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer

et al. 2021

View full text Add to dashboard Cite

Ovarian cancer (OC) is a devastating malignancy with a poor prognosis. The complex tumor immune microenvironment results in only a small number of patients benefiting from immunotherapy. To explore the different factors that lead to immune invasion and determine prognosis and response to immune checkpoint inhibitors (ICIs), we established a prognostic risk scoring model (PRSM) with differential expression of immune-related genes (IRGs) to identify key prognostic IRGs. Patients were divided into high-risk and low-risk groups according to their immune and stromal scores. We used a bioinformatics method to identify four key IRGs that had differences in expression between the two groups and affected prognosis. We evaluated the sensitivity of treatment from three aspects, namely chemotherapy, targeted inhibitors (TIs), and immunotherapy, to evaluate the value of prediction models and key prognostic IRGs in the clinical treatment of OC. Univariate and multivariate Cox regression analyses revealed that these four key IRGs were independent prognostic factors of overall survival in OC patients. In the high-risk group comprising four genes, macrophage M0 cells, macrophage M2 cells, and regulatory T cells, observed to be associated with poor overall survival in our study, were higher. The high-risk group had a high immunophenoscore, indicating a better response to ICIs. Taken together, we constructed a PRSM and identified four key prognostic IRGs for predicting survival and response to ICIs. Finally, the expression of these key genes in OC was evaluated using RT-qPCR. Thus, these genes provide a novel predictive biomarker for immunotherapy and immunomodulation.

show abstract

Section: Discussionmentioning

confidence: 56%

Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The relevance of safety for HCC patients was also acknowledged in earlier studies with tyrosine kinase inhibitors, wherein a preliminary endoscopic assessment was considered essential [87][88][89]. As such, attempts to define an immune signature that can help to tailor the best treatment for each subtype are especially welcome and have recently been gaining attention [17,[90][91][92].…”

Section: Discussionmentioning

confidence: 99%

The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma

Montella

Sarno

Ambrosino

et al. 2021

Cells

View full text Add to dashboard Cite

In contrast to several tumors whose prognoses are radically affected by novel immunotherapeutic approaches and/or targeted therapies, the outcomes of advanced hepatocellular carcinoma (HCC) remain poor. The underlying cirrhosis that is frequently associated with it complicates medical treatment and often determines survival. The landscape of HCC treatment had included sorafenib as the only drug available for ten years, until 2018, when lenvatinib was approved for treatment. The second-line systemic treatments available for hepatocellular carcinoma include regorafenib, cabozantinib, ramucirumab, and, more recently, immune checkpoint inhibitors. However, the median survival remains below 15 months. The results obtained in clinics should be interpreted whilst considering the peculiar role of the liver as an immune organ. A healthy liver microenvironment ordinarily experiences stimulation by gut-derived antigens. This setup elucidates the response to chronic inflammation and the altered balance between tolerance and immune response in HCC development. This paper provides an overview of the mechanisms involved in HCC pathogenesis, with a special focus on the immune implications, along with current and future clinical perspectives.

show abstract

“…We further examined the predictive efficacy of immunotherapy in the TCGA cohort. IPS analysis and TIDE analysis were two methods most frequently applied in bioinformatic studies (Wu et al, 2021;Xu R. et al, 2021;Xu Y. et al, 2021;Zhao et al, 2021;Zuo et al, 2021). The IPS analysis results suggested that the SRLncSig might present a better performance in predicting CTLA4 blockade therapy.…”

Section: Discussionmentioning

confidence: 99%

Integrated Analysis of Stemness-Related LncRNAs Helps Predict the Immunotherapy Responsiveness of Gastric Cancer Patients

Jiang

Chen

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The immune microenvironment plays a critical role in tumor biology. As a critical feature of cancers, stemness is acknowledged as a contributor to the development of drug resistance in gastric cancers (GCs). Long non-coding RNAs (lncRNAs) have been revealed to participate in this process. In this study, we aimed to develop a stemness-related lncRNA signature (SRLncSig) with guiding significance for immunotherapy. Three cohorts (TCGA, Zhongshan, and IMvigor210) were enrolled for analysis. A list of stemness-related lncRNAs (SRlncRNAs) was collected by co-expression strategy under the threshold of coefficient value >0.35 and p-value < 0.05. Cox and Lasso regression analysis was further applied to find out the SRlncRNAs with prognosis-predictive value to establish the SRLncSig in the TCGA cohort. IPS and TIDE algorithms were further applied to predict the efficacy of SRLncSig in TCGA and Zhongshan cohorts. IMvigor210 was composed of patients with clinical outcomes of immunotherapy. The results indicated that SRLncSig not only was confirmed as an independent risk factor for GCs but also identified as a robust indicator for immunotherapy. The patient with a lower SRLncSig score was more likely to benefit from immunotherapy, and the results were highly consistent in three cohorts. In conclusion, our study not only could clarify the correlations between stemness and immunotherapy in GC patients but also provided a model to guide the applications of immunotherapy in clinical practice.

show abstract

Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma

Cited by 21 publications

References 39 publications

Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer

Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer

The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma

Integrated Analysis of Stemness-Related LncRNAs Helps Predict the Immunotherapy Responsiveness of Gastric Cancer Patients

Contact Info

Product

Resources

About